SCHEDULE: Goldman Sachs Discloses 2.9% Stake in Indivior Pharmaceuticals

Goldman Sachs Group and its subsidiary, Goldman Sachs & Co. LLC, reported a 2.9% beneficial ownership stake in Indivior Pharmaceuticals, Inc. as of December 31, 2025.

Summary

• The Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, jointly reported beneficial ownership of 3,592,430.80 shares of Indivior Pharmaceuticals, Inc. common stock.
• This ownership represents 2.9% of Indivior Pharmaceuticals' outstanding common stock.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• Goldman Sachs & Co. LLC holds shared voting power over 3,592,395.80 shares and shared dispositive power over 3,592,430.80 shares.
• This filing is an Amendment No. 3 to a Schedule 13G, indicating an update to a previously reported ownership position.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It is a routine disclosure of beneficial ownership by a major financial institution, with no indication of strategic changes or significant shifts in the issuer's prospects.

Positives

• The disclosure confirms Goldman Sachs' continued investment in Indivior Pharmaceuticals, signaling institutional interest.
• The stated purpose of holding shares 'in the ordinary course of business' suggests a passive investment, reducing concerns about potential activist intervention.

Negatives

• The 2.9% stake is below the 5% threshold that typically triggers more significant market attention, suggesting a relatively minor position for a large institutional investor.

Risks

• No specific risks to Indivior Pharmaceuticals, Inc. are identified in this filing, as Goldman Sachs explicitly states its holdings are not for the purpose of changing or influencing control.

Industry Context

StockSavvy.ai notes that institutional ownership disclosures like this Schedule 13G provide transparency into major investors' positions. While Goldman Sachs' 2.9% stake in Indivior Pharmaceuticals is not a controlling interest, it reflects continued institutional confidence in the pharmaceutical sector, particularly in companies like Indivior that focus on specialized treatments. This level of ownership is typical for large financial institutions managing diverse portfolios.

Comparison to Industry Standards

• Goldman Sachs' 2.9% stake in Indivior Pharmaceuticals is a standard passive investment for a large financial institution, falling well below the 5% threshold that often signals a more strategic or activist position.
• Activist investors like Carl Icahn or Elliott Management typically accumulate stakes significantly above 5% to exert influence, whereas a diversified financial services firm like Goldman Sachs often holds smaller, non-controlling positions across numerous companies as part of its asset management activities.
• This position is comparable to similar passive holdings by other major investment banks or asset managers in the pharmaceutical sector, such as BlackRock or Vanguard, which routinely report sub-5% stakes in a wide array of public companies.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially offering a minor boost to confidence due to Goldman Sachs' involvement, but unlikely to cause major price movements given the passive nature and percentage.
• Employees, Customers, Suppliers, Creditors: No direct impact is indicated by this beneficial ownership report.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of a passive, non-controlling stake by a major financial institution. It does not provide new information regarding Indivior Pharmaceuticals' operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The 2.9% ownership by Goldman Sachs is typical for a diversified portfolio and explicitly states no intent to influence control. Therefore, a "hold" recommendation is appropriate, as the filing itself does not present a compelling reason to buy or sell, and investors should rely on more comprehensive financial reports for investment decisions.

Keywords

Indivior Pharmaceuticals, Goldman Sachs, Schedule 13G, beneficial ownership, common stock, institutional investment, SEC filing, G4766E116, pharmaceutical